Specialized Resource A - Cyclotron Radiochemistry and Chemistry (SR-A). lCMlC-3 is reliant on the production and supply of existing and novel radiopharmaceuticals and radiochemicals. In this Specialized Resource we will continue to generate a tool box of radiolabeled drugs based around 18F-tracers as well as drugs based on the longer-lived nuclides 64Cu, 86Y, 89Zr and 124I. This will allow us to augment the existing lCMIC-3 projects, the ICMIC Developmental Projects, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients.
The Specific Aims of this Specialized Resource are as follows: (A) to undertake specialized radiochemistry and labeling chemistry in support of the ICMIC projects and developmental projects;(B) To function as an evolving resource - to provide (and design) new compounds as required as the ICMIC research matures; and, (C) to act as a central resource for the translation of new drugs to the clinical setting.
The Aims will be achieved by providing state-of-the-art radiochemistry facilities (including a $25M expansion over the next 5 years) to the ICMIC projects and developmental projects with high grade, GMP prepared (if required) radiotracers. This Specialized Resource will also be developmental in nature;as new chemicals and radiochemicals are required by the Projects, this Specialized Resource will respond by producing novel compounds as requested.

Public Health Relevance

This Specialized Resource will provide services and expertise in chemistry and radiochemistry to all four of the Research Projects within this ICMIC. This Specialized Resource we will generate a tool box of radiolabeled drugs that will allow us to augment the existing ICMIC projects, the ICMIC developmental projects and the new ICMIC research programs, ultimately resulting in the ability to get a better understanding of the biology of cancer and to perform personalized medicine in our patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Cheal, Sarah M; Xu, Hong; Guo, Hong-fen et al. (2014) Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 13:1803-12
de Biasi, Andreas R; Villena-Vargas, Jonathan; Adusumilli, Prasad S (2014) Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20:5384-91
Vargas, Hebert Alberto; Wassberg, Cecilia; Fox, Josef J et al. (2014) Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 271:220-9
Adusumilli, Prasad S (2014) Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma. Cancer 120:3268-71
Eguchi, Takashi; Kadota, Kyuichi; Park, Bernard J et al. (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210-22
Zhang, Hanwen; Huang, Ruimin; Pillarsetty, NagaVaraKishore et al. (2014) Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging 41:322-32
Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94
Zhang, Hanwen; Huang, Ruimin; Cheung, Nai-Kong V et al. (2014) Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res 20:2182-91
Beattie, Bradley J; Pentlow, Keith S; O'Donoghue, Joseph et al. (2014) A recommendation for revised dose calibrator measurement procedures for 89Zr and 124I. PLoS One 9:e106868
Lee, Ming-Ching; Buitrago, Daniel H; Kadota, Kyuichi et al. (2014) Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. Lung Cancer Manag 3:245-253

Showing the most recent 10 out of 119 publications